Zealand Pharma — September 2022
-
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting...
-
-
Zealand Pharma sagsøgt for misbrug af forretningshemmeligheder
Da et potentielt samarbejde kuldsejlede, tog Zealand Pharma fortrolig viden fra modparten med sig. Det mener et græsk biotekselskab, der har sagsøgt Zealand Pharma i Danmark og USA.
(medwatch.dk)
-
-
-
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European...
GlobeNewswire News Room (www.globenewswire.com)
*BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase
-
“We are delighted with the data presented at EASD from Boehringer Ingelheim’s Phase 2 trial of the dual glucagon/GLP-1 receptor agonist BI 456906 that showed effective lowering of HbA1c of up to -1.88% in people with type 2 diabetes at 16 weeks compared to -1.47% observed following open-label treatment with the GLP-1 receptor agonist semaglutide,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma.
-
Zealand Pharma har afgørende data klar om få uger. Zealand Pharma har afsluttet sit fase 3-forsøg med lægemiddelkandidaten glepaglutid og venter nu på de afgørende data, så de kan deles med offentligheden.
Det skriver Finans. https://medwatch.dk/Medicinal___Biotek/article14425346.ece?utm_campaign=MedWatch Morgen&utm_content=2022-09-22&utm_medium=email&utm_source=medwatch -
Den generelle markedsnedtur presser igen Modelporteføljen:
Den generelle markedsnedtur presser igen Modelporteføljen
Menuen står igen på tilbagegang på de generelle markeder, og det rammer også modelporteføljen, som siden sidst er gået pænt tilbage
Økonomisk Ugebrev (ugebrev.dk)
... også lidt omkring Zealand Pharma.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind